Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to the COVID-19 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have active solid tumor malignancy diagnosis~2. On active chemotherapy~3. Received two prior SARS-COV2 Pfizer vaccines~4. Age ≥ 18 years~5. Ability to understand and the willingness to sign a written informed consent~6. Agree to comply with study procedures~7. Subjects previously enrolled under the main study~Exclusion Criteria:~1. History of HIV or organ/bone marrow transplant~2. Actively receiving immunotherapy~3. On active, chronic immunosuppression (\>10 mg daily dose of prednisone equivalent)~4. Currently incarcerated or residence of another state~5. Speaks a language other than English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3rd COVID-19 vaccine (2nd booster) (Type: EXPERIMENTAL): Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).